Clinical TrialJul 7, 2026, 06:06 AM
Molecular Partners Updates Clinical Progress for Radio-DARPin Pipeline
AI Summary
Molecular Partners AG provided an update on its targeted alpha Radio-DARPin therapeutics pipeline, highlighting significant clinical progress. Dosing is ongoing in the Phase 1/2a study of MP0712, with initial data anticipated in the coming months and comprehensive efficacy data expected in 2027. The company also announced the initiation of a compassionate care program for a DLL3-targeting Radio-DARPin in South Africa, demonstrating the versatility of its DARPin platform. Additionally, first-in-human imaging for MP0726 is planned for H2 2026, with a new target nomination in H2 2026 and two INDs planned for 2027.
Key Highlights
- MP0712 Phase 1/2a trial dosing is ongoing for DLL3-targeted Radio-DARPin.
- Initial MP0712 data expected in coming months, comprehensive efficacy data in 2027.
- Compassionate care program for DLL3 Radio-DARPin (MP0714) initiated in South Africa.
- MP0726 (MSLN-targeted Radio-DARPin) first-in-human imaging planned for H2 2026.
- New Radio-DARPin target nomination expected in H2 2026.
- Two Investigational New Drug (IND) applications planned for 2027.
Price Impact
More from MOLN